CLINICAL TRIALS PROFILE FOR ESBRIET

All Clinical Trials for ESBRIET

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001596 ↗	Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome	Completed	National Human Genome Research Institute (NHGRI)	Phase 2	2005-09-01	Hermansky-Pudlak Syndrome (HPS) is an inherited disease that results in decreased pigmentation (oculocutaneous albinism), bleeding problems due to a platelet abnormality (platelet storage pool defect), and storage of an abnormal fat-protein compound (lysosomal accumulation of ceroid lipofuscin). The disease can cause poor functioning of the lungs, intestine, kidneys, or heart. The most serious complication of the disease is pulmonary fibrosis and typically causes death in patients 40 - 50 years old. The disorder is common in Puerto Rico, where many of the clinical research studies on the disease have been conducted. Neither the full extent of the disease nor the basic cause of the disease is known. There is no known treatment for HPS. The drug pirfenidone blocks the biochemical process of inflammation and has been reported to slow or reverse pulmonary fibrosis in animal systems. In this study researchers will select up to 40 HPS patients diagnosed with pulmonary fibrosis. The patients will be randomly divided into 2 groups. The patients will not know if they are taking pirfenidone or a placebo "sugar pill". 1. Group one will be patients who will receive pirfenidone. 2. Group two will be patients who will receive a placebo "sugar pill" The major outcome measurement of the therapy will be a change in the lung function (forced vital capacity). The study will be stopped if one therapy proves to be more effective than the other.
NCT00001596 ↗	Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome	Completed	William Gahl, M.D.	Phase 2	2005-09-01	Hermansky-Pudlak Syndrome (HPS) is an inherited disease that results in decreased pigmentation (oculocutaneous albinism), bleeding problems due to a platelet abnormality (platelet storage pool defect), and storage of an abnormal fat-protein compound (lysosomal accumulation of ceroid lipofuscin). The disease can cause poor functioning of the lungs, intestine, kidneys, or heart. The most serious complication of the disease is pulmonary fibrosis and typically causes death in patients 40 - 50 years old. The disorder is common in Puerto Rico, where many of the clinical research studies on the disease have been conducted. Neither the full extent of the disease nor the basic cause of the disease is known. There is no known treatment for HPS. The drug pirfenidone blocks the biochemical process of inflammation and has been reported to slow or reverse pulmonary fibrosis in animal systems. In this study researchers will select up to 40 HPS patients diagnosed with pulmonary fibrosis. The patients will be randomly divided into 2 groups. The patients will not know if they are taking pirfenidone or a placebo "sugar pill". 1. Group one will be patients who will receive pirfenidone. 2. Group two will be patients who will receive a placebo "sugar pill" The major outcome measurement of the therapy will be a change in the lung function (forced vital capacity). The study will be stopped if one therapy proves to be more effective than the other.
NCT00076102 ↗	Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas	Completed	National Cancer Institute (NCI)	Phase 2	2004-07-21	Background: Neurofibromatosis Type 1 (NF1) is an autosomal dominant, progressive genetic disorder characterized by diverse clinical manifestations. Patients with NF1 have an increased risk of developing tumors of the central and peripheral nervous system including plexiform neurofibromas, which are benign nerve sheath tumors that may cause severe morbidity and possible mortality. The histopathology of these tumors suggests that events connected with formation of fibroblasts might constitute a point of molecular vulnerability. Gene profile analysis demonstrates overexpression of fibroblast growth factor, epidermal growth factor, and platelet-derived growth factor in plexiform neurofibromas in patients with NF1. Pirfenidone is a novel antifibrotic agent that inhibits these and other growth factors. Clinical experience in adults has demonstrated that pirfenidone is effective in a variety of fibrosing conditions and pirfenidone is presently under study in a phase II trial for adults with progressive plexiform neurofibromas. A phase I trial of pirfenidone in children and young adults with NF1 and plexiform neurofibromas was completed, and has established the phase II dose (the dose resulting in a mean drug exposure [AUC] not more than 1 standard deviation below the mean drug exposure [AUC] in adults who received pirfenidone at the dose level demonstrating activity in fibrosing conditions). Pirfenidone has been well tolerated. Objectives: To determine whether pirfenidone increases the time to disease progression based on volumetric measurements in children and young adults with NF1 and growing plexiform neurofibromas. To define the objective response rate to pirfenidone in NF1-related plexiform neurofibromas. To describe and define the toxicities of pirfenidone. Eligibility: Individuals (greater than or equal to 3 years to less than or equal to 21 years of age) with a clinical diagnosis of NF1 and inoperable, measurable, and progressive plexiform neurofibromas that have the potential to cause substantial morbidity. Design: The phase II dose will be used in a single stage, single arm phase II trial The natural history of the growth of plexiform neurofibromas is unknown. For this reason, time to disease progression on the placebo arm of an ongoing National Cancer Institute (NCI) Pediatric Oncology Branch (POB) placebo-controlled, double-blind, cross-over phase II trial of the farnesyltransferase inhibitor R115777 for children and young adults with NF1 and progressive plexiform neurofibromas. Funding source - Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD)

Clinical Trial Conditions for ESBRIET

Condition Name

Condition Name for ESBRIET
Intervention	Trials
Idiopathic Pulmonary Fibrosis	5
Interstitial Lung Disease	2
Disorder Related to Lung Transplantation	2

Condition MeSH

Condition MeSH for ESBRIET
Intervention	Trials
Pulmonary Fibrosis	8
Idiopathic Pulmonary Fibrosis	5
Fibrosis	5

Clinical Trial Locations for ESBRIET

Trials by Country

Trials by Country for ESBRIET
Location	Trials
United States	62
Italy	14
Spain	10
Canada	7
Germany	5

Trials by US State

Trials by US State for ESBRIET
Location	Trials
California	5
Michigan	4
New York	4
Massachusetts	4
Maryland	4

Clinical Trial Progress for ESBRIET

Clinical Trial Phase

Clinical Trial Phase for ESBRIET
Clinical Trial Phase	Trials
Phase 4	2
Phase 2/Phase 3	1
Phase 2	12

Clinical Trial Status

Clinical Trial Status for ESBRIET
Clinical Trial Phase	Trials
Completed	9
Recruiting	4
Active, not recruiting	3

Clinical Trial Sponsors for ESBRIET

Sponsor Name

Sponsor Name for ESBRIET
Sponsor	Trials
Genentech, Inc.	6
Hoffmann-La Roche	5
University of Michigan	2

Sponsor Type

Sponsor Type for ESBRIET
Sponsor	Trials
Other	23
Industry	13
NIH	4

ESBRIET (nintedanib): Clinical Trials Update, Market Analysis, and Projection

Last updated: April 26, 2026

What is ESBRIET and what is its current clinical positioning?

ESBRIET is nintedanib (oral), marketed by Boehringer Ingelheim. It is approved for idiopathic pulmonary fibrosis (IPF) and for progressive fibrosing interstitial lung diseases (PF-ILD) depending on jurisdiction and label. The drug’s commercial durability hinges on (1) continuing penetration in IPF, (2) growth into PF-ILD indications, and (3) competitive pressure from antifibrotics and emerging pipeline assets targeting fibrotic disease pathways.

Core indication set used in market models

• IPF: disease-modifying use aligned with antifibrotic standard of care.
• PF-ILD: expansion into broader fibrosing ILD populations where eligibility depends on clinical criteria used in trials and payer formularies.

Regulatory and clinical backbone

• The IPF efficacy and safety foundation for nintedanib comes from the INPULSIS program (and broader clinical development in IPF).
• PF-ILD expansion derives from the INBUILD trial.

(See cited sources: [1]-[4].)

---

Which clinical trials are most relevant to ESBRIET in 2024–2026 watchlists?

Clinical updates for nintedanib cluster into three buckets: IPF maintenance, PF-ILD label expansion and conversion to routine practice, and combination or next-line studies in fibrotic ILD.

1) PF-ILD: INBUILD program follow-through

• INBUILD established efficacy in PF-ILD, providing the basis for label expansion in multiple geographies.
• Commercial impact comes less from new endpoints and more from real-world conversion: guideline uptake, payer acceptance, and physician comfort with long-term dosing.

Key reference trial

• INBUILD (PF-ILD): randomized controlled evidence of slowing decline in lung function. (Source: [2].)

2) IPF: ongoing comparative and durability evidence

• IPF remains the highest-volume fibrosis indication.
• Clinical updates in IPF often take the form of subgroup analyses, real-world evidence, and head-to-head comparative modeling against other antifibrotics (pirfenidone).

Key reference trial

• INPULSIS: IPF efficacy and safety foundation. (Source: [1].)

3) Emerging combination and next-gen fibrosis research

• Nintedanib’s clinical relevance in combination strategies is frequently evaluated against pathways overlapping with fibrosis progression.
• For market decision-making, combination trials matter only if they produce labeling or payer-relevant differentiation versus existing antifibrotics.

Key practical point for investors

• Without label expansion or clear clinical superiority that changes standard-of-care sequencing, incremental benefit usually translates into modest share gains, not category redefinition.

(Trial backbone citations: [1], [2].)

---

What is the competitive landscape for ESBRIET?

Direct antifibrotic comparator

• Pirfenidone (other oral antifibrotic for IPF) competes for the same patient pool, payer budgets, and treatment-naïve and switched patient decisions.

Category competition

• PF-ILD is a broader battlefield where treatment eligibility is more heterogeneous. ESBRIET’s share gains depend on:
  • strictness of progression criteria used in practice,
  • access and reimbursement decisions,
  • and physician selection patterns informed by trial populations.

(Clinical grounding for nintedanib’s IPF and PF-ILD positioning: [1]-[4].)

---

How does the market structure today translate into revenue drivers?

ESBRIET revenue is driven by:

1. Patient prevalence and diagnosis rates in IPF and PF-ILD.
2. Treatment uptake as guidelines and formularies align to antifibrotic use.
3. Persistence (continuation dosing) and dose intensity (adherence and tolerability).
4. Price and reimbursement, including discounting dynamics by payer and tendering.

Market sizing mechanics used for projection

A standard projection approach for antifibrotics uses:

• Eligible patient pool estimates (IPF + PF-ILD under label-relevant definitions)
• Treatment penetration (share of eligible patients receiving nintedanib or competing antifibrotics)
• Therapy duration and adherence
• Average Net Price (ANP) after rebates and discounts

Because the request is a market analysis and projection, the projection below focuses on drivers that can move the curve rather than static epidemiology alone.

---

Market analysis and projection: What growth path fits ESBRIET?

Base case thesis

ESBRIET is expected to deliver mid-single-digit to low-double-digit growth in the near term where:

• PF-ILD uptake expands faster than IPF switching rates,
• real-world treatment eligibility captures a meaningful share of the PF-ILD population,
• and payer coverage sustains or improves.

Upside path

• Wider payer adoption of PF-ILD criteria, reduced access barriers, and higher persistence.
• More robust guideline incorporation in PF-ILD clinical pathways.
• Competitive pressure remains contained (few disruptive entrants with better efficacy and labeling in the same populations).

Downside path

• Competitive substitution shifts toward another antifibrotic in specific geographies.
• Tolerability and dosing discontinuation pressures reduce effective persistence.
• Payer controls tighten, limiting PF-ILD patient capture.

---

What do historical performance signals imply for 2025–2028?

Boehringer Ingelheim discloses therapeutic area and portfolio performance; nintedanib is a core antifibrotic asset within that strategy. While ESBRIET’s year-to-year sales have fluctuated with label adoption and competition, the structural basis for continued growth is:

• IPF volume remains stable as a chronic disease with ongoing incident cases.
• PF-ILD offers incremental addressable population beyond IPF.
• Oral chronic dosing supports scaling with physician adoption and managed care alignment.

Key supporting references for the drug’s role in IPF and PF-ILD include regulatory and trial documentation. (Sources: [1]-[4].)

---

Projection framework: How should investors model ESBRIET revenue?

Three levers

1. Eligible population (E)

   • IPF incident and diagnosed prevalence
   • PF-ILD progression-based eligibility capture rate

2. Share of treated patients (S)

   • competition with pirfenidone in IPF
   • sequencing dynamics in PF-ILD

3. Effective price and persistence (P)

   • net pricing after rebates
   • adherence and discontinuation rates

Scenario table (directional, for business planning)

Scenario	E (Eligible capture)	S (Treated share)	P (Net price + persistence)	Revenue implication (direction)
Base	Moderate PF-ILD capture, stable IPF	Share stable to modest gains	Price stable, persistence steady	Sustained growth
Upside	Faster PF-ILD adoption + broader eligibility capture	Share gains in PF-ILD cohorts	Improved persistence; managed care support	Faster growth
Downside	Slower PF-ILD capture, tighter payer rules	Share erodes in IPF switching	Lower ANP, higher discontinuation	Flattening or decline

This model aligns to how antifibrotic assets typically perform: steady baseline from IPF with step-change from PF-ILD adoption. (Clinical foundations: [1], [2].)

---

Key risks that can change the trajectory

1) Payer eligibility and reimbursement rules

PF-ILD outcomes depend on whether payers cover the patient segments that clinical trials included. Narrow coverage reduces E even if incidence increases.

2) Differentiation vs competitive therapy

If pirfenidone (or other pathway agents in the future) secures better tolerability or easier dosing in real-world PF-ILD subsets, ESBRIET share can drift.

3) Safety and tolerability leading to persistence loss

Even without safety label changes, real-world dose reductions can reduce effective treatment exposure.

---

What is the 2024–2026 commercial “watch list” for ESBRIET?

1. PF-ILD conversion metrics: increases in treated patient count relative to IPF.
2. Geographic reimbursement: expansion or tightening across major markets.
3. Real-world persistence: discontinuation rates and dose intensity over time.
4. Competitive switching patterns in IPF.

These items are actionable because they connect directly to E, S, and P in the projection framework.

---

Key Takeaways

• ESBRIET is anchored in IPF (INPULSIS) and expanded to PF-ILD (INBUILD), with commercial performance driven by PF-ILD uptake and persistence rather than only incident-case growth. ([1], [2])
• Competitive dynamics are dominated by pirfenidone in IPF, while PF-ILD share depends on payer coverage and clinician eligibility alignment to trial-like progression criteria.
• The most important forecast variable for 2025–2028 is PF-ILD eligible capture; IPF provides the stable baseline while PF-ILD drives incremental growth. ([1]-[4])

---

FAQs

1) Is ESBRIET a single-indication drug or does it cover broader fibrosis disease?

ESBRIET is used beyond IPF through PF-ILD label expansion in jurisdictions where the regulatory basis is supported by INBUILD. ([2], [3])

2) What trial evidence most directly supports ESBRIET’s market expansion?

INBUILD supports PF-ILD expansion; INPULSIS supports the IPF base. ([1], [2])

3) What competes with ESBRIET in IPF?

Pirfenidone is the primary competing oral antifibrotic for IPF treatment decisions. (Background clinical context: [1].)

4) Which commercial lever matters most for ESBRIET growth?

The key lever is PF-ILD treatment eligibility capture and payer adoption, since IPF volume is more stable and PF-ILD adds incremental addressable patients. ([2], [4])

5) Do clinical trial updates typically change ESBRIET’s revenue outlook?

Only updates that affect label scope, eligibility criteria, payer access, or clear differentiation versus competitors are likely to meaningfully shift revenue trajectories. The label and evidence base are anchored by INPULSIS and INBUILD. ([1], [2])

---

References

[1] Richeldi, L., et al. (2014). Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis (INPULSIS). The New England Journal of Medicine.
[2] Flaherty, K. R., et al. (2019). Nintedanib in progressive fibrosing interstitial lung diseases (INBUILD). The New England Journal of Medicine.
[3] European Medicines Agency. (n.d.). Ofev: EPAR summary for the public (nintedanib).
[4] U.S. Food and Drug Administration. (n.d.). OFEV (nintedanib) prescribing information.